All In Biotech

Drug Trial Radar · NCT07521683

A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 20, 2025

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Lead sponsor
NeuShen TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-group Phase II study to preliminarily evaluate the efficacy and safety of NS-136 in patients with schizophrenia. The study consists of a screening period, baseline period, treatment period, and follow-up period, with the screening period lasting up to 21 days. Eligible subjects will be randomized in a 1:1:1 ratio to the 80 mg (QD) group, 120 mg (QD) group, or placebo group. The study drug treatment will last for 5 weeks, followed by a 2-week safety follow-up after completion of the study.

Conditions

  • Schizophrenia(Acute)

Interventions

  • NS-136Drug

    NS136 80mg and 120mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive And Negative Syndrome Scale(PANSS )scoreTime frame: Week 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NeuShen

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.